Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Art Academies in China: Global Histories and Institutional Practices (CHINACADEMY)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Consolidator grants
Action type: ERC actions
Panel: Texts and Concepts
Panel description: Literary studies , literature,  philosophy
Countries involved: Germany
Call: ERC CONSOLIDATOR GRANTS (ERC-2021-COG, 2021)
Start date: 2023-09-01
End date: 2028-08-31
Duration (months): 60.0
Total project cost (EUR): 1955208.0
EU funding (EUR): 1955208.0
Participants: 1
Project status: SIGNED

Art academies played an essential role in shaping modern art in China. They were the sites where European methods of art education were introduced; where the social role of the modern artist was defined; where the importance of traditional art forms and training methods was negotiated; where art history as a modern field was established; and where political and ideological changes in artistic practices were first implemented. Today, art academies incorporate laboratories of innovation as well as academic curricula inherited from the socialist period. Thus, they are emblematic of the dynamics within the Chinese cultural sphere and society at large, and of the tensions between a rapid globalization on the one hand and the preservation of cultural heritage and national identity discourses on the other. By studying art academies, their global histories and institutional practices, as the most significant actors in modern Chinese art, CHINACADEMY offers new understandings of the aesthetic, social, and political conditions of artistic creation in modern and contemporary China. Tracing the transnational connections to Japan, France, the Soviet Union, and other regions, it shows how institutional structures and artistic practices were adapted to the requirements of Chinese society in acts of cultural translation. It questions existing narratives of modernization, conservation, and political influence in art by highlighting personal affiliations, the agency of institutions, issues of conflict, and gendered experiences. These will be excavated through oral histories as well as archival records. By stressing the importance of academic and traditionalist practices, CHINACADEMY also decentres the paradigm of modernism that is still prevalent in global histories of modern art. It thereby proposes a new perspective for a global art history that pushes beyond Eurocentric as well as Sinocentric narratives.
Virtual screening for supporting cell programming platform based on Targeted Nanoparticles (Nano-engine hop on)

Framework: Horizon Europe — Widening Participation and Strengthening the European Research Area
Programme: Widening participation and spreading excellence
Theme: Improved access to Excellence
Destination: Improved access to Excellence
Action type: Research and Innovation actions
Countries involved: Netherlands,Poland
Call: Hop on Facility (HORIZON-WIDERA-2023-ACCESS-06, 2023)
Duration (months): 27.0
Total project cost (EUR): 358492.5
EU funding (EUR): 358492.5
Participants: 2
Project status: SIGNED

The overall aim of the NANO-ENGINE project is to establish preclinical proof of the concept for the first in vivo cell engineering platform technology by demonstrating efficient in vivo transfection of bone marrow cells and preliminary efficacy in treatment of CD19+ B cell malignancies. Integration of the new widening partner (QSARL) will enhance the projects objectives through the application of in silico methods i.e., machine learning algorithms and molecular docking simulations to identify the most effective structures of formulation’s componentsnanoparticle formulation and their optimal ratio of each of the individual components for stable, durable, safe and efficacious Targeted Nanoparticlein vivo T cell targeting. Additionally, through integration of in silico approaches into the project methodology, the Consortium will gain support in optimizing the process of product development and manufacturing in terms of relevant parameters, such as time and costs. The new widening partner will increase the visibility of the project through online activities: information on the project on the QSARL webpage, posts in social media, scientific articles and communicates rising awareness about advanced cell therapies in society, participation in webinars and workshops, as well as dissemination of the project results through the participation in major international conferences, exhibitions, and fairs.

Keywords: virtual screening,in silico studies,machine learning,molecular docking,targeted nanoparticles
Algorithmics of Stochastic Principal-Agent Coordination (ASPAC)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Computer Science and Informatics
Panel description: Informatics and information systems, computer science, scientific computing, intelligent systems
Countries involved: United Kingdom
Call: ERC STARTING GRANTS (ERC-2025-STG, 2025)
Start date: 2026-01-01
End date: 2030-12-31
Duration (months): 60.0
Total project cost (EUR): 1499957.0
EU funding (EUR): 1499957.0
Participants: 1
Project status: SIGNED

When making decisions, autonomous agents rely on their own incentives and private information. When these factors diverge, conflicts can arise, leading to inefficiencies or suboptimal outcomes. Economists have studied this phenomenon under the principal-agent framework, where the principal seeks to coordinate the agents so that the agents' rational choices align with the principal's objectives. This framework is gaining increasing attention, especially in the era of AI, where automated agents become more capable of making decisions autonomously. In computer science, algorithmic approaches to principal-agent coordination strategies have become an area of growing interest, giving rise to influential subfields, such as algorithmic information design, contract design, and automated mechanism design. Despite this progress, much of the literature focuses on static, one-shot models, which fall short of capturing the complexities of real-world problems occurring in stochastic environments. These problems are inherently dynamic and involve sequential decision-making. Solving them requires addressing fundamentally new computational challenges arising from the interplay between the complexities of the principal-agent model and the dynamics and stochasticity of the environment. This project aims to tackle these challenges by investigating the computational and algorithmic foundations of stochastic principal-agent coordination (SPAC). The goal is to introduce a useful framework for formalising SPAC and develop algorithms and computational theories regarding the tractability, approximability, and learnability of problems within the framework. By exploring these fundamental aspects, we expect the project to substantially advance the theoretical literature while contributing algorithmic solutions to real-world applications of SPAC.

Keywords: principal agent problem,sequential decision making,stochastic games,stackelberg games,information design,bayesian persuasion,contract design,automated mechanism design,optimal commitment,computational complexity
NeuroClues: the clinical must-have for Neurologists: clinical validation, industrialization, and go-to-market. (NeuroClues: the clinical must-have for Neurologist)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Open to supporting projects in all areas of science, technology,...
Action type: EIC actions
Countries involved: Belgium
Call: EIC Accelerator Open (HORIZON-EIC-2022-ACCELERATOR-01, 2022)
Start date: 2023-02-01
End date: 2027-01-31
Duration (months): 48.0
Total project cost (EUR): 5557786.5
EU funding (EUR): 2500000.0
Participants: 1
Project status: SIGNED

P3Lab developed NeuroClues, a first-of-a-kind portable, fast and easy to use eye tracking medical device that brings clinically validated eye movement biomarkers for movement disorders (MDs) into the clinical routine of neurologists. NeuroClues will enable neurologists to establish their MD diagnosis faster (from months to days) earlier and more reliably, and with diagnostic grade accuracy. This will enable neurologists to start patient care earlier. This project aims at validating and demonstrating (I) the usability of NeuroClues in the clinical routine with early adopter KOL neurologists and (II) assess its clinical value in ongoing and (III) in own sponsored clinical investigation studies (EU and US). This is needed to convince the broad majority of neurologist of NeuroClues’ clinical value. The successful demonstration and accompanied development of our go-to-market strategy will enable P3Lab to become investor ready by 2024 and profitable by 2027, with €70M ARR targeted by 2030.
Eco-friendly and high-performance thermal insulating fibre reinforced mortar to be applied on walls as a coating or panel (Eco-Mortar 2.0)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Information Science and Engineering
Countries involved: Portugal
Call: MSCA Postdoctoral Fellowships 2022 (HORIZON-MSCA-2022-PF-01, 2022)
Start date: 2023-10-02
End date: 2025-10-01
Duration (months): 24.0
Total project cost (EUR): 156778.56
EU funding (EUR): 156778.56
Participants: 1
Project status: SIGNED

One of the priorities of the 2030 Agenda is to achieve a sustainable development path to balance environmental, social and economic needs for present and future generations. The United Nations Sustainable Development Goals (SDGs) are the blueprint to achieve a better and more sustainable future. The Green Deal is the roadmap towards the application of the 2030 Agenda and the SDGs in all European policies. In this context, the European construction industry faces great challenges that need real solutions. On the environment side, it is clearly a sector with an unsustainable environmental profile that will need to overcome the traditional linear path of production and consumption to adopt a Circular Economy model and Energy Efficient solutions. The number of studies on new sustainable solutions to minimize the incorporation of processed raw materials or improve thermal insulation properties of mortar have increased. Examples relate to the use of stone sludge waste from the cutting process as filler in rendering mortars or fibres from textile waste to reduce its cracking or to the increased insulation of rendering mortars through the incorporation of cork (recycled by-product of the cork industry) or silica-based aerogels (nano-structured material) as lightweight aggregates. However, studies focused on combination stone sludge waste, textile waste, recycled cork together with aerogel in mortars have not been found in the current literature. The main objective of the Eco-Mortar 2.0 project is to develop an eco-friendly and high-performance thermal insulating fibre reinforced rendering mortar for wall exterior retrofitting or wall panels coating of buildings by using diabase sludge from stone cutting as filler, recycled cork and aerogel granules as lightweight aggregates and textile waste as fibres. This mortar will decrease the use of non-renewable natural resources, improve thermal insulation and allow shrinkage cracking control.

Keywords: circular economy,energy efficient,environmental,durability,mortar,waste,nanotechnology,thermal insulation,high performance,filler,fibre,aggregate,diabase sludge,textile,cork,aerogel
Accelerated deployment of integrated CCUS chains based on solvent capture technology (AURORA)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Climate, Energy and Mobility
Theme: Energy
Destination: Sustainable, secure and competitive energy supply
Action type: Innovation actions
Countries involved: Norway,France,United Kingdom,Italy,Greece,Belgium
Call: Decarbonising industry with CCUS (HORIZON-CL5-2022-D3-01, 2022)
Start date: 2023-01-01
End date: 2026-06-30
Duration (months): 42.0
Total project cost (EUR): 15734176.46
EU funding (EUR): 12196763.33
Participants: 12
Project status: SIGNED

Rapid up-scaling and deployment of more cost-efficient and sustainable carbon capture solutions is needed to reduce the emissions of CO2-intensive industries. Solvent-based carbon capture is an important technology that can be readily adopted to many emission sources. Such technology can achieve high capture rates and deliver CO2 at high purity with a relatively low energy demand. In AURORA the open and non-proprietary CESAR1 solvent technology will be optimised and qualified for commercial deployment. The technology will be demonstrated at TRL7-8 for three CO2 intensive industries: refining, cement, and materials recycling, for which there are few other options to achieve climate neutrality. The partners will demonstrate negligible environmental impact (emissions being a potential issue for solvent technology), capture rates at 98%, and capture costs reduced by at least 47% compared to a benchmark process with the MEA solvent. This will be achieved due to the following innovations: 1) Holistic optimisation of solvent composition, process design, emission monitoring and control, and solvent management, 2) Validated models for use in commercial process simulators 3) enhanced waste heat integration with carbon capture for reduced external heat demand and operational costs 4) Improved and integrated advanced control system for reduced OPEX and optimised performances. These innovations will be integrated in four optimised capture processes and various aspects will be demonstrated in pilots of various size and complexity. The partners will ensure transferability of results to other CO2 intensive industries thanks to the large variations in CO2 source and developed clusters addressed in the project and a strong stakeholder participation. The project will also do full CCUS chain assessments for its end-users. It is noteworthy that the end-users are situated in two different regions of Europe offering different conditions for the implementation of CCUS value chains.

Keywords: absorption solvents ccus value chains,nmpc
The first IVDR-approved commercial software solutions for AI-powered RNA-based companion and precision cancer diagnostics of acute myeloid leukaemia and bladder cancer (QIandQD)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Challenges
Action type: EIC actions
Countries involved: Sweden
Call: EIC Accelerator Challenge: Novel biomarker-based assays to guide personalised cancer treatment (HORIZON-EIC-2023-ACCELERATOR-01, 2023)
Start date: 2024-05-01
End date: 2027-04-30
Duration (months): 36.0
Total project cost (EUR): 3559500.0
EU funding (EUR): 2491650.0
Participants: 1
Project status: SIGNED

Qlucore is developing visualisation-based analytical solutions with an established position in the next-generation sequencing (NGS) market. As pioneers in RNA-data analysis, we aim to revolutionise the field of companion and clinical diagnostics by developing software platforms integrating AI-powered machine-learning classification models for gene expression signatures and gene fusion analysis. By providing highly accurate and specific diagnoses, our platform represents the future of precision oncology, putting Europe at the forefront of AI-powered cancer classification. A software-based setup speeds up the introduction of new clinical guidelines and companion diagnostic solutions with the ultimate purpose of increasing survival rates and overall health. We aim to cover all cancer types relevant for gene expression-based diagnostics, and then scale up into non-cancer indications (e.g. cardiovascular and neurological diseases, immunological disorders) and other data types (e.g. proteomics and single-cell RNA-seq), further disrupting the precision diagnostics industry. Currently, we are preparing the solution with a classification model for B-cell progenitor acute lymphoblastic leukaemia (BCP-ALL) for the first IVDR certification (proof of concept). Building on those achievements and leveraging regulatory and data management experience, and progress, in the proposed project we will focus on acute myeloid leukaemia (AML) and bladder cancer (BC). For AML and BC we will develop and CE-certify classification models and companion diagnostics (CDx)-specific classification models. The successful completion of this project will significantly improve Europe's position in genomics- and AI-based precision diagnostics and as such prompt similar initiatives across Europe. This will allow the EU to compete effectively with market leaders (in particular the US) and offer significant benefits to patients diagnosed with cancer and society as a whole.

Keywords: rna seq,artificial intelligence,machine learning,precision cancer diagnostics,gene fusions,gene expression signatures,software as a medical device,companion diagnostic software
First-In-Class N-Glycosylation Inhibitors for Selective Treatment of Cancers and other Serious Diseases (THE PHOSTINES)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: France
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 24.0
Total project cost (EUR): 2500000.0
EU funding (EUR): 2500000.0
Participants: 1
Project status: SIGNED

Despite the advances in cancer therapies, today rare types of cancer with high rates of relapse such as glioblastoma multiforme (GBM) and triple negative breast cancer (TNBC) have limited therapeutic options, representing a large unmet medical need. In this type of aggressive tumors, cancer cells show changes in glycosylation with the formation of a complex abnormal glycan pattern that acts as a shield masking the tumor cells from the immune system, and increasing their ability to proliferate. These changes contribute to cancer progression, metastasis and evasion of immune response. Based on 10 years of research, Phost’in uniquely impairs the shield formation, acting from the INSIDE of the cell to unmask cancer to the immune system. We have developed a unique discovery platform that enables the discovery and development of a new class of therapeutics that targets key glycosylation mechanisms responsible for cancer progression and immune escape. Our first family of molecules, The Phostines, selectively inhibits N-acetylglucosaminyltransferase-V (GnT-V), a glycosyltransferase encoded by the Mgat5 gene that promotes growth and metastasis in dependent solid tumors while hampering their immune response. Our lead asset PhOx430 is currently evaluated in Europe in a Phase I/II in patients with advanced solid tumors (PhAST trial). Preliminary results showed very positive results regarding safety and activity. PhOx430 has also demonstrated pre-clinical efficacy on fibrosis models. Data attracted a first pharma company, Taiho pharmaceuticals, with a regional (Japan) option deal in 2023. With the EIC support, we will bring PhOx430 to the end of phase I/II clinical trials for further licensing to a global pharma, prepare new clinical studies in combination with current chemo-and immunotherapies, conduct regulatory studies to bring PhOx430 ready for Phase I clinical trial in fibrosis and discover new assets to extend our pipeline.

Keywords: immuno oncology,glycosylation inhibitors,solid tumors,glioblastoma,triple negative breast cancer tnbc,chemotherapy,glycobiology,cancer,fibrosis
New Genomic Techniques for Next Generation Viticulture (NG-VINES)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Italy
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 24.0
Total project cost (EUR): 1300000.0
EU funding (EUR): 1300000.0
Participants: 1
Project status: SIGNED

The grapevine industry is struggling with economic challenges due to plant diseases and climate change, necessitating new grapevine varieties to ensure productivity and quality. EdiVite srl, an Italian startup founded in 2020 as a spin-off from Verona University, aims to address these challenges by genetically improving grapevines for increased resistance to pathogens and environmental stress. Edivite’s innovative approach uses New Genomic Techniques (NGT) to achieve precise, targeted mutations, or "genome editing," without introducing foreign DNA, thus preserving the quality of traditional varieties. Genome editing holds immense potential for agriculture, as evidenced by proposed new EU regulations on NGTs. EdiVite has patented a method for applying genome editing to grapevines, positioning the company to revolutionize viticulture. The business model includes producing edited grapevines and managing pre-commercialization phases before selling or licensing them to nurseries for propagation in Europe and beyond. The company has already produced edited plants for two varieties, Chardonnay and Glera, which represent 25% of the national nursery market with around 30 million cuttings annually. Full-scale commercialization is expected by 2030, with projected royalties of approximately 6 million Euros per year. The business is poised for scalable growth, with an expected annual increase of 13%, driven by expansion into other varieties. As a global leader with no direct competitors, EdiVite must rapidly scale up to maintain its competitive edge. A 1.3 million Euro grant from the European Innovation Council (EIC) would expedite the open-field demonstration of prototypes, support certification and authorization processes, establish partnerships, and bridge the gap between research and market, advancing EdiVite's pioneering solutions in sustainable viticulture.

Keywords: new genomic techniques ngt,grapevine,pathogen resistance,sustainable viticulture,protoplasts,crispr cas9 system,dna free,preservation of genetic makeup
Full qualification, testing and commercial deployment of a unique on-chip memory technology offering the highest-density embedded memory in a standard CMOS process (GCRAM)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Open to supporting projects in all areas of science, technology,...
Action type: EIC actions
Countries involved: Israel
Call: EIC Accelerator Open 2024 (HORIZON-EIC-2024-ACCELERATOR-02, 2024)
Start date: 2024-07-01
End date: 2026-06-30
Duration (months): 24.0
Total project cost (EUR): 3571427.14
EU funding (EUR): 2499999.0
Participants: 1
Project status: SIGNED

The Memory Bottleneck has become a major concern in modern Systems-on-a-Chip and hence, the size of on-chip embedded memory continues to increase, already reaching up to 75% of the total SoC real estate. However, the industry standard SRAM technology is very area-inefficient and has been facing major scaling difficulties in modern process technologies (beyond 10nm). RAAAM’s Gain-Cell Random Access Memory (GCRAM) technology is a unique on-chip memory solution that only requires 2-3 transistors to store a bit of data, as opposed to 6-8 transistors needed for the existing SRAM-based highest-density memory technology. The solution is area efficient, cost-effective and can be manufactured using the standard CMOS process. Having successfully tested the technology in various nodes ranging from 180nm-16nm, RAAAM currently aims to develop, fabricate, and characterize the proposed memory technology for nodes ≤5nm and to fully qualify it for production according to industry standards

Keywords: off chip memory accesses,cmos process nodes,memory,finfet technology,semiconductor